Hemodynamic Effects of Ketone Bodies in Patients With Pulmonary Hypertension.
echocardiography
invasive hemodynamics
ketone bodies
pulmonary arterial hypertension
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
16 05 2023
16 05 2023
Historique:
medline:
18
5
2023
pubmed:
15
5
2023
entrez:
15
5
2023
Statut:
ppublish
Résumé
Background Pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) are debilitating diseases with a high mortality. Despite emerging treatments, pulmonary vascular resistance frequently remains elevated. However, the ketone body 3-hydroxybutyrate (3-OHB) may reduce pulmonary vascular resistance in these patients. Hence, the aim was to assess the hemodynamic effects of 3-OHB in patients with PAH or CTEPH. Methods and Results We enrolled patients with PAH (n=10) or CTEPH (n=10) and residual pulmonary hypertension. They received 3-OHB infusion and placebo (saline) for 2 hours in a randomized crossover study. Invasive hemodynamic and echocardiography measurements were performed. Furthermore, we investigated the effects of 3-OHB on the right ventricle of isolated hearts and isolated pulmonary arteries from Sprague-Dawley rats. Ketone body infusion increased circulating 3-OHB levels from 0.5±0.5 to 3.4±0.7 mmol/L (
Identifiants
pubmed: 37183871
doi: 10.1161/JAHA.122.028232
pmc: PMC10227291
doi:
Substances chimiques
Ketone Bodies
0
Banques de données
ClinicalTrials.gov
['NCT04615754']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e028232Références
Eur Respir J. 2020 Apr 9;55(4):
pubmed: 32108049
Circ Res. 1958 May;6(3):357-62
pubmed: 13523819
Circ Heart Fail. 2013 Jul;6(4):845-52
pubmed: 23733915
Eur J Pharmacol. 2018 Jun 15;829:121-128
pubmed: 29679541
Am J Cardiol. 1995 Jan 19;75(3):55A-62A
pubmed: 7840056
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
Circulation. 2019 Apr 30;139(18):2129-2141
pubmed: 30884964
J Am Coll Cardiol. 2021 Apr 6;77(13):1660-1669
pubmed: 33637354
Br J Pharmacol. 2004 Jan;141(1):105-13
pubmed: 14656807
J Am Heart Assoc. 2017 Feb 27;6(3):
pubmed: 28242634
Elife. 2020 Sep 21;9:
pubmed: 32955439
Eur Respir J. 2002 Oct;20(4):965-71
pubmed: 12412690
Scand J Clin Lab Invest. 1991 Nov;51(7):605-13
pubmed: 1810020
Am J Physiol. 1996 May;270(5 Pt 1):E746-51
pubmed: 8967461
Circ Res. 1977 Jul;41(1):19-26
pubmed: 862138
Am J Physiol Heart Circ Physiol. 2005 Aug;289(2):H938-46
pubmed: 15805229
Basic Res Cardiol. 1995 Sep-Oct;90(5):388-96
pubmed: 8585860
Crit Care. 2001 Dec;5(6):355-61
pubmed: 11737925
Am J Respir Cell Mol Biol. 2016 Apr;54(4):451-60
pubmed: 26744837
Am J Physiol Lung Cell Mol Physiol. 2019 Sep 1;317(3):L361-L368
pubmed: 31242024
BMJ Open Diabetes Res Care. 2016 Apr 29;4(1):e000202
pubmed: 27158520
J Clin Monit Comput. 2005 Dec;19(6):395-9
pubmed: 16437290
Circulation. 2016 Feb 23;133(8):689-91
pubmed: 26819375
Circ Res. 1979 Feb;44(2):166-75
pubmed: 216503
Am J Physiol Heart Circ Physiol. 2013 Apr 15;304(8):H1060-76
pubmed: 23396451
Physiol Rep. 2017 Oct;5(19):
pubmed: 29038355
Crit Care. 2014 Mar 25;18(2):R48
pubmed: 24666826
Circ Res. 2014 Jun 20;115(1):115-30
pubmed: 24951762
Mayo Clin Proc. 2009 Feb;84(2):191-207
pubmed: 19181654
Eur Respir J. 2015 Mar;45(3):700-8
pubmed: 25359353
FASEB J. 1995 May;9(8):651-8
pubmed: 7768357
Circ Heart Fail. 2021 Jan;14(1):e007684
pubmed: 33356362
Metabolism. 1979 Jan;28(1):41-50
pubmed: 759825
J Clin Endocrinol Metab. 1987 Aug;65(2):331-8
pubmed: 3298305